# A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

> **NCT06137482** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN13335
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT06137482
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-06
- **Primary completion:** 2025-02-11
- **Final completion:** 2025-02-11
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06137482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06137482, "A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06137482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*